The clearance expands the robotic platform to support natural orifice, single-port, and multiport procedures on a single system.
The US Food and Drug Administration granted 510(k) clearance for the multiport configuration of the Anovo Surgical System, Momentis Surgical announced. The clearance expands the platform beyond its previous indications, making it the first robotic surgical system capable of supporting natural orifice, single-port, and multiport access on a single platform.
The system uses proprietary instruments inspired by human anatomy, featuring shoulder-, elbow-, and wrist-like joints. These internally articulated instruments allow surgeons to use a conventional multiport approach while utilizing the same core platform previously cleared for other procedures. This modularity allows general surgeons to choose between single-site and multiport approaches for ventral hernia repair and provides gynecologic surgeons with a multiport option for transvaginal and single-site procedures.
“From the beginning, our vision was never to build another robotic system that simply replicated laparoscopy,” says Dvir Cohen, CEO of Momentis Surgical, in a release. “We set out to rethink robotic surgery from the inside out. This clearance represents another important step toward that vision by giving surgeons the flexibility to choose the appropriate surgical approach for the patients’ benefit while using the same compact robotic platform.”
Unlike conventional robotic systems that rely on rigid instruments and large external movements, the Anovo system shifts the point of articulation inside the patient. This design minimizes external robotic arm movement and the risk of arm collisions while maintaining 360-degree dexterity at the surgical site. The compact architecture is intended to improve access to robotic surgery in both hospital and outpatient settings, such as ambulatory surgery centers, by reducing capital requirements and simplifying workflows.
“The future of robotic surgery will not be defined by a single access technique,” says Maurice R Ferré, MD, chairman of Momentis Surgical, in a release. “Surgeons need the flexibility to select the best approach for each patient. With this clearance, Anovo becomes a truly adaptable platform capable of supporting natural orifice, single-port, and multiport procedures within one unified robotic ecosystem.”
The new clearance follows several regulatory milestones for the company, including the first De Novo authorization for a robotic transvaginal surgical system and clearances for ventral hernia repair. Momentis Surgical expects the expanded indication to broaden the clinical use of the platform and accelerate commercialization efforts.
Photo caption: Momentis Surgical’s Anovo Surgical System is a robotic surgery platform designed to support natural orifice, single-port, and multiport minimally invasive procedures. The FDA has cleared the system’s multiport configuration, making it the first robotic platform capable of supporting all three surgical access approaches on a single system, according to a release from the company.
Photo credit: Momentis Surgical
